The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Improvements in Neurocognitive Function and Mood Following Adjunctive Treatment with Mifepristone (RU-486) in Bipolar Disorder
Open accessAbstract
High cortisol levels are found in severe mood disorders, particularly bipolar disorder. Hypercortisolaemia may cause or exacerbate both neurocognitive impairment and depressive symptoms. We hypothesized that antiglucocorticoid treatments, particularly corticosteroid receptor antagonists, would improve neurocognitive functioning and attenuate depressive symptoms in this disorder. To test this hypothesis, 20 bipolar patients were treated with 600 mg/day of the corticosteroid receptor antagonist mifepristone (RU-486) or placebo for 1 week in a double-blind crossover design. Over the total 6 weeks of the study, neurocognitive and neuroendocrine function were evaluated at baseline, days 21 and 42. Mood symptoms were evaluated weekly. Nineteen subjects completed the protocol; there were no drop-outs due to adverse events. Following treatment with mifepristone, selective improvement in neurocognitive functioning was observed. Spatial working memory performance was significantly improved compared to placebo (19.8% improvement over placebo). Measures of verbal fluency and spatial recognition memory were also improved after mifepristone. Beneficial effects on mood were found; Hamilton Depression Rating Scale scores were significantly reduced compared to baseline (mean reduction of 5.1 points) as were Montgomery-Asberg Depression Rating Scale scores (mean reduction of 6.05 points). No significant change occurred after placebo. These data require replication but provide preliminary evidence that glucocorticoid receptor antagonists may have useful cognitive-enhancing and possibly antidepressant properties in bipolar disorder.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“drugs targeting the HPA axis can improve BD symptoms (Young et al. 2004;Young ,2014;Juruena et al. 2009).”
From The HPA axis in bipolar disorder: Systematic review and meta-analysis (2016) · cites this paper as Young et al. 2004
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 3×
“…symptomatic improvement, the antidepressant effect of mifepristone was the principal focus, therefore the outcome measures of interest were the 17-item Hamilton Depression Rating Scale (HDRS17; Hamilton, 1960) and the Montgomery–Asberg Depression Rating Scale (MADRS; Montgomery and Asberg, 1979).”
MethodInfluentialA new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · cited 3×
“…symptomatic improvement, the antidepressant effect of mifepristone was the principal focus, therefore the outcome measures of interest were the 17-item Hamilton Depression Rating Scale (HDRS17; Hamilton, 1960) and the Montgomery–Asberg Depression Rating Scale (MADRS; Montgomery and Asberg, 1979).”
MethodInfluentialKessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370 · cited 1×
“Bipolar disorder is a chronic and recurrent illness, with a lifetime incidence of at least 1% (Kessler et al, 1994).”
BackgroundThe Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090 · cited 1×
“Other secondary scales consisted of the Brief Psychiatric Rating Scale (BPRS; Overall and Gorham, 1962) and the Young Mania Rating Scale (YMRS; Young et al, 1978).”
MethodA Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744 · cited 1×
“Other secondary scales consisted of the Brief Psychiatric Rating Scale (BPRS; Overall and Gorham, 1962) and the Young Mania Rating Scale (YMRS; Young et al, 1978).”
MethodNeuropsychological assessment.
Cipolotti, L., & Warrington, E. K. (1995) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.58.6.655 · Cited by 3,234
The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106 · cited 1×
“Although the illness is defined by the occurrence of mania, the depressed phase predominates (Judd et al, 2002, 2003) and represents the greatest therapeutic challenge.”
BackgroundGlucocorticoids and Hippocampal Atrophy in Neuropsychiatric Disorders
Sapolsky, R. M. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.10.925 · Cited by 2,016 · cited 2×
“It has been suggested that abnormalities in hypothalamic–pituitary– adrenal (HPA) axis function may cause or exacerbate both neurocognitive impairment and depressive symptoms (McQuade and Young, 2000; Sapolsky, 2000).”
BackgroundSmithson, M. (2000) · SAGE Publications Ltd eBooks · doi:10.4135/9781446218525 · Cited by 1,871
Judd, L. L., Akiskal, H. S., Schettler, P. J., Coryell, W., Endicott, J., Maser, J. D., Solomon, D. A., Leon, A. C., & Keller, M. B. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.3.261 · Cited by 1,243 · cited 1×
“Although the illness is defined by the occurrence of mania, the depressed phase predominates (Judd et al, 2002, 2003) and represents the greatest therapeutic challenge.”
Background
Research works printed but not linked: 5
- Cegalis J, Bowlin J (1991). Vigil: Software for the Assessment of Attention. Forthought: Nashua, NH.
- First MB, Spitzer RL, Williams JBW, Gibbon M (1995). Structured Clinical Interview for DSM-IV (SCID-I), Research Version. Biometrics Research Department, New York State Psychiatric Institute: New York.
- Høyberg ØJ, Wik G, Mehtonen OP, Peeters BWMM, Sennef C (2002). ORG 34517, a selective glucocorticoid receptor antagonist with potent antidepressant activity: first clinical results. Int J Neuropsychopharmacol 5: S148.
- Lopez JF, Little KY, Lopez-Figueroa AL, Lopez-Figueroa MO, Watson SJ (2003). Glucocorticoid and mineralocorticoid receptor mRNA levels in the hippocampus and prefrontal cortex of subjects with mood disorders and schizophrenia. Biol Psychiatry 53: 489.
- Thompson JM, Gray JM, Hughes J, Watson S, Ferrier I, Young AH (2000). A component process analysis of working memory dysfunction in bipolar affective disorder. J Psychopharmacol (Oxf) 14: A24.
Cited by
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Stress and the brain: from adaptation to disease
de Kloet, E. R., Joëls, M., & Holsboer, F. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1683 · Cited by 4,621
The HPA axis in major depression: classical theories and new developments
Pariante, C. M., & Lightman, S. L. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.06.006 · Cited by 2,009
Keller, J., Gomez, R., Williams, G., Lembke, A., Lazzeroni, L., Murphy, G. M., & Schatzberg, A. F. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.120 · Cited by 922
“In addition, Young's group reported that the GR antagonist mifepristone significantly improves visual memory in bipolar depression (31).”
BackgroundThe glucocorticoid receptor: Pivot of depression and of antidepressant treatment?
Anacker, C., Zunszain, P. A., Carvalho, L. A., & Pariante, C. M. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2010.03.007 · Cited by 592
Metadata
- Authors
- Young, A. H., Gallagher, P., Watson, S., Del-Estal, D., Owen, B. M., & Nicol Ferrier, I.
- Affiliations
- Newcastle University (GB)
- Corresponding author
- Young, Allan H
- Venue
- Neuropsychopharmacology
- Published
- 2004-05-05
- Volume
- 29
- Issue
- 8
- Pages
- 1538-1545
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2041573038
- Cited by
- 318
- References
- 38
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 13 · 2023: 6 · 2022: 2 · 2021: 11 · 2020: 9 · 2019: 5 · 2018: 14 · 2017: 8 · 2016: 16 · 2015: 13 · 2014: 18 · 2013: 12 · 2012: 14
- FWCI
- 15.34
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Stanley Medical Research Institute
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- mifepristone, RU486, bipolar disorder, glucocorticoid receptor antagonist, hypercortisolism, neurocognitive function, spatial working memory, verbal fluency, spatial recognition memory, depressive symptoms, antidepressant effects, cognitive enhancement
- MeSH terms
- Adult, Affect, Attention, Bipolar Disorder, Cognition, Double-Blind Method, Female, Hormone Antagonists, Humans, Hydrocortisone, Learning, Male, Memory, Short-Term, Middle Aged, Psychiatric Status Rating Scales, Psychomotor Performance, Receptors, Glucocorticoid, Space Perception, Verbal Learning, Mifepristone, Treatment Outcome, Cross-Over Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Improvements in Neurocognitive Function and Mood Following Adjunctive Treatment with Mifepristone (RU-486) in Bipolar Disorder. https://app.cochat.ai/papers/10.1038/sj.npp.1300471
- The paper
- Young, A. H., Gallagher, P., Watson, S., Del-Estal, D., Owen, B. M., & Nicol Ferrier, I. (2004). Improvements in Neurocognitive Function and Mood Following Adjunctive Treatment with Mifepristone (RU-486) in Bipolar Disorder. Neuropsychopharmacology. https://doi.org/10.1038/sj.npp.1300471
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.